top of page

Multiple Myeloma MRD guidelines

Amit Garg
Oct 29
1 min read

The updated NCCN Multiple Myeloma Guidelines, Version 1.2027 (September 9, 2026), now provide specific recommendations for when to perform measurable residual disease (MRD) testing, including clonoSEQ.



NCCN-recommended MRD testing timepoints

Timepoint

Recommendation

At diagnosis

Obtain baseline clonotype identification for future NGS testing (once only).

After induction therapy

Assess depth of response.

After autologous stem cell transplant

Approximately day +100 (3 months).

After CAR T-cell therapy

Approximately 3 months after infusion.

After treatment for relapse or major regimen change

Reassess MRD response.

During maintenance therapy

Annually as a general recommendation.

During surveillance

Generally annually, individualized to clinical circumstances.


 
 
 

Recent Posts

See All
5 Lab clues you are Iron Deficient

 1. Ferritin<30 ng/mL. Ferritin<100 ng/mL if inflammation, autoimmune diseases, cancer 2. Low transferrin saturation (TSAT) <20% suggests insufficient circulating iron availability 3. MCV <80 indicate

 
 
 

Comments


bottom of page